Advanced chondrosarcomas: Role of chemotherapy and survival

A. Italiano, O. Mir, A. Cioffi, E. Palmerini, S. Piperno-Neumann, C. Perrin, L. Chaigneau, N. Penel, F. Duffaud, J. E. Kurtz, O. Collard, F. Bertucci, E. Bompas, A. Le Cesne, R. G. Maki, I. Ray, J. Y. Blay

Research output: Contribution to journalArticlepeer-review


Background: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. Methods: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed. Results: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS. Conclusions: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.

Original languageEnglish
Article numbermdt374
Pages (from-to)2916-2922
Number of pages7
JournalAnnals of Oncology
Issue number11
Publication statusPublished - Nov 2013


  • Chemotherapy
  • Chondrosarcoma
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Hematology


Dive into the research topics of 'Advanced chondrosarcomas: Role of chemotherapy and survival'. Together they form a unique fingerprint.

Cite this